FDA Panel Endorses GRAIL's Galleri Test; GRAL Stock Reflects High Price-to-Sales Amid Unprofitability

As reported by gurufocus.com

On September 23, 2026, a U.S. FDA advisory panel voted 6-4 in favor of GRAIL Inc’s (NASDAQ: GRAL) Galleri multi-cancer early detection blood test, deeming it ...

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on gurufocus.com ↗

Market Samachar is a news aggregator. This article was originally published by gurufocus.com. Tap the button above to read the full story on their site.

COMPANIES NSE becomes 9th most valued company with Rs 4.63 lakh crore m-cap after IPO. Who did it overtake? Stocks-Markets-Economic Times
COMPANIES PB Fintech among 4 F&O stocks with a sharp rise in futures open interest Stocks-Markets-Economic Times
COMPANIES Steel Authority of India among 3 stocks showing White Marubozu pattern Stocks-Markets-Economic Times
COMPANIES NSE shares jump 5% after muted debut, market value swells by Rs 19,290 crore. Why Macquarie, other brokerages are bullish Stocks-Markets-Economic Times
COMPANIES Why is market falling today? Sensex tumbles over 700 points, Nifty below 23,200. 5 factors behind Rs 4 lakh crore wipeout Stocks-Markets-Economic Times
INDIAN Genesys International spurts after winning Rs 283 crore Ahmedabad digital twin contract Share Market Today
INDIAN Avantel share price soars 9% in weak market on heavy volume Share Market Today
INDIAN NSE debut disappoints: Can it deliver long-term gains? Experts weigh in Share Market Today

FDA Panel Endorses GRAIL's Galleri Test; GRAL Stock Reflects High Price-to-Sales Amid Unprofitability

More from Market Samachar